Gedatolisib
- Generic Name
- Gedatolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H41N9O4
- CAS Number
- 1197160-78-3
- Unique Ingredient Identifier
- 96265TNH2R
- Background
Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Risk Adjusted Net Present Value: What is the current valuation of Celcuity's Gedatolisib
Gedatolisib's US revenue forecasted at $137 mn by 2034, with risk-adjusted NPV (rNPV) model used for investment valuation. Gedatolisib targets dual PI3K/mTOR for various cancers, while Celcuity's diagnostic platform identifies patient populations for targeted therapies. Celcuity reported operating and net losses of $39.4 mn and $40.4 mn in FY2022.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath